Sodium Alginate

Summary

Sodium Alginate (CHEMBL2108744) is a phase-3 clinical-stage unknown; indicated across 2 conditions including gastroesophageal reflux disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108744
Name	Sodium Alginate
Type	Unknown
Max phase	3

Also known as: Algin, Alginic acid, sodium salt, E-401, FEMA NO. 2014, Hydagen 558 p, INS NO.401, INS-401, Sodium alginate, Sodium alginate component of ntx-1, SODIUM ALGINATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastroesophageal reflux disease	3	MONDO:0007186	EFO:0003948

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02277886	PHASE4	UNKNOWN	Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances
NCT04134364	PHASE4	COMPLETED	The Effect of Lamina-G on Gastrointestinal Symptom After Gastric Biopsy
NCT06367452	PHASE4	COMPLETED	Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate
NCT01338077	PHASE3	COMPLETED	Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease
NCT01450748	PHASE3	COMPLETED	Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux
NCT06426134	Not specified	COMPLETED	Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).